TOPIC

Biomedicine: Companies

Related Topics:
Biomedicine: Companies
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
A worker checks the position of a feeding tray in a pharmaceutical manufacturing facility at the Hengrui Biomedical Industrial Park in Lianyungang in Jiangsu province, on December 13, 2021. Photo: Getty Images
China economy

Opinion | How China engineered the rapid rise of its drug innovation industry

A market once dominated by generics is now an AI-powered pharmaceutical hub drawing billion-dollar investments from the likes of Pfizer and GSK.

videocam
Hong Kong stock market

China’s 3SBio seeks US$400 million in Hong Kong to boost drug pipeline

Biomedicine: Industry Trends

China’s clinical trial capacity matches US, attracts more global pharma firms

New medical drugs

6 of the best: the billion-dollar biotechs putting China on the map

China’s biotech renaissance is gathering pace as home-grown innovators strike billion-dollar licensing deals with global giants.

Illustration: Henry Wong
Hong Kong healthcare and hospitals

Hong Kong biotech firm to back controversial sanitary pad HPV test with evidence

Dr Choi Pui-wah, founder of WomenX Biotech, also says she remains optimistic about Hong Kong as a tech destination despite government warning.

Biomedicine: Industry Trends

China biotech forum bills antibody cancer drugs as next-generation treatment

Biotech insiders tout antibody-drug conjugates as the next big thing in cancer treatment, with firms urged to pursue global strategies.

Advertisement
Advertisement
Advertisement
Greater Bay Area

BeOne Medicines to expand cancer-drug offerings in Hong Kong

Fresh off a profitable half year, a global drug company that started as an R&D firm in Beijing plans to expand production in Guangzhou.

A facility manufacturing cancer drugs in Guangzhou. Photo: Handout
Hong Kong stock market

China’s Akeso gets share boost as data shows cancer drug’s benefits

Lung-cancer drug ivonescimab is ‘potentially two to three years ahead of competitors’, analyst says.

Biomedicine: Science

Hansoh and Leads Biolabs clinch US$2.5 billion in global drug licensing deals

Two mainland biotech firms win global attention as Roche and Dianthus sign major licensing pacts, highlighting China’s growing role in next-generation drug development.

HKEX

HKEX’s new Hang Seng Biotech Index Futures to debut next month

The futures contracts platform aims to meet offshore investors’ heightened interest in Hong Kong-listed Chinese biopharmaceutical stocks.

The Hang Seng Biotech Index Futures will track the performance of the 30 largest Hong Kong-listed Chinese pharmaceutical and medical device companies. Photo: Shutterstock
Start-ups

Singapore’s Nanyang Biologics to list on Nasdaq amid Trump’s pharma tariffs

The start-up agrees to merge with a special-purpose acquisition company in a deal that puts its value at US$1.5 billion.

Nanyang Biologics expects to become a player in the US$30 billion market for AI-based drug discovery. Photo: Shutterstock
Greater Bay Area

Hong Kong MRI maker Time Medical seeks site to boost output, eyes IPO

Aiming to grow sales to US$300 million in 2027, the company is eyeing a Nasdaq IPO and then a Hong Kong secondary listing.

China-Africa relations

China’s ‘health silk road’ in Africa gets a boost with insulin, pharma projects

Move to manufacture insulin locally is set against forecast of nearly 55 million Type 2 diabetes cases in sub-Saharan Africa by 2045.

videocam
Biomedicine: Science

Mirxes wins China’s approval to launch groundbreaking gastric cancer blood test

The non-invasive blood test helps in the early detection of the fifth leading cause of cancer deaths globally.

GastroClear, the first microRNA blood test approved in China for the early detection of gastric cancer, evaluates risks by detecting 12 miRNA biomarkers, according to developer Mirxes. Photo: Handout
IPO

Exclusive | Hong Kong ‘critical’ as investors ‘rediscover’ China: Morgan Stanley

City’s capital market lets innovative Chinese companies ‘position longer-term value propositions to the global investor base’, banker says.

Shane Zhang, head of Asia-Pacific investment banking at Morgan Stanley. Illustration: Lau Ka-kuen
Health & Fitness

Li Ka-shing-backed focused ultrasound therapy treats 1 millionth case

The therapy, which uses ultrasound energy to treat a number of diseases including cancer, is gaining global traction, a US expert says.

United States

China’s pharmaceutical sector surges amid growth in sales, licensing income

Strong growth momentum and global push expected to continue, HSBC says.

Advertisement
Advertisement
Advertisement
IPO

Chinese healthcare, biotech firms flock to Hong Kong for IPOs

September yields at least 23 listing applications from mainland biotech firms eyeing the city’s lucrative fundraising market.

The Hang Seng Biotech index, which tracks the 50 largest biotech, pharmaceutical and medical-device firms listed in Hong Kong, has surged 109 per cent this year. Photo: Shutterstock
Baidu

Baidu-backed drug discovery start-up Biomap challenges Google’s AlphaFold

Biomap expects to double its revenue this year, co-founder and CEO Wei Liu says.

Biomedicine: Geopolitics

Trump’s tariffs on imported drugs ‘not a big concern’ for China’s pharma firms

Chinese drug makers have ‘minimal sales exposure to the US’, Jefferies analysts say.

Biomedicine: Industry Trends

Pfizer’s Metsera acquisition to spur Chinese search for new weight drugs

The deal, worth up to US$7.3 billion, will encourage ongoing investment by mainland players but not draw in new rivals, analysts say.

The Pfizer deal is not good news for Chinese firms developing weight-loss drugs with the aim of reducing injections, an analyst says. Photo: Shutterstock
Jiangsu Hengrui Pharmaceuticals

China’s Hengrui gets boost from fifth drug-licensing deal of year

Shares rise after Mumbai-based Glenmark Pharmaceuticals strikes deal for cancer drug.

A worker checks a machine at Hengrui Biomedical Industrial Park in Lianyungang, in East China’s Jiangsu province, on December 13, 2021. Photo: Future Publishing via Getty Images
US-China relations

Opinion | Why US-China health and drugs cooperation must top Trump-Xi agenda

The years-long impasse harms both nations and the world, and the stakes in global health security could not be higher.

videocam
Health in China

Beijing tackles drug price wars with new tendering rules in anti-involution push

China’s new drug procurement rules prioritise quality over price in a bid to curb cutthroat competition.

Biomedicine: Industry Trends

Ascletis trial shows drug candidate ASC47 boosts semaglutide weight loss effect

Chinese biotech firm is among dozens of mainland drug makers seeking to compete in the global market for diabetes and weight-loss drugs.

China’s weight-loss drugs market could grow to US$5.6 billion in 2035, according to Goldman Sachs. Photo: Shutterstock
Hong Kong stock market

Chinese biotechs get a shot in the arm from policy support, licensing deals

‘We are on an upcycle in the industry and sentiment is very strong,’ Xufunds Investment fund manager Wang Chen says.

Shares of WuXi Biologics have more than doubled year to date. Photo: Shutterstock
US-China tech war

Chinese 3D biomolecule imaging start-up aims for IPO in 2027

Shuimu BioSciences is the first Chinese company to develop its own cryo-electron microscopy machine, a vital tool in drug discovery.

ETFs

Chinese biotech ETFs attract investors amid US$60 billion of licensing deals

Funds from the US are flowing into biotech ETFs as investors seek unique opportunities to beat the market, China AMC’s Heidi Cai says.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement